相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Continuous Real-World Gait Monitoring in Idiopathic REM Sleep Behavior Disorder
Silvia Del Din et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease
Nirosen Vijiaratnam et al.
DRUGS (2020)
Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes
Ruth Brauer et al.
BRAIN (2020)
Analysis of Free-Living Gait in Older Adults With and Without Parkinsons Disease and With and Without a History of Falls: Identifying Generic and Disease-Specific Characteristics
Silvia Del Din et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2019)
Post hoc analysis of the Exenatide-PD trial-Factors that predict response
Dilan Athauda et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease A Secondary Analysis of the Exenatide-PD Trial
Dilan Athauda et al.
JAMA NEUROLOGY (2019)
Treatment advances in Parkinson disease: Same script different cast?
Nirosen Vijiaratnam et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis
Joanna C. Crocker et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
New Perspectives on Study Designs for Evaluating Neuroprotection in Parkinson's Disease
Laetitia Thibault et al.
MOVEMENT DISORDERS (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length
Silvia Del Din et al.
JOURNAL OF NEUROENGINEERING AND REHABILITATION (2016)
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Iciar Aviles-Olmos et al.
BRAIN (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Lisa M. Shulman et al.
ARCHIVES OF NEUROLOGY (2010)
Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
Claire L. Tomlinson et al.
MOVEMENT DISORDERS (2010)
TCH346 as a neuroprotective drug in Parkinsons disease: a double-blind, randomised, controlled trial
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron
T Perry et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons
H Yamamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
A novel neutrotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
分享论文
